Skip to content
RDL
Network
Ecosystem
Switch app
TR
About
FAQ
Sign in
Get started
Sodium‐glucose cotransporter 2 inhibitors: An additional management option for patients with atrial fibrillation? — Riccardo Proietti (2022) | RDL Network
Back
Cite
Save
Save for later
Share
Home
Publications
Sodium‐glucose cotransporter 2 inhibitors: An additional management option for patients with atrial fibrillation?
Shared by
Professor Gregory Lip
University of Liverpool
Sodium‐glucose cotransporter 2 inhibitors: An additional management option for patients with atrial fibrillation?
Article
2022
en
Authors
RP
Riccardo Proietti
Professor Gregory Lip
University of Liverpool
Discussion
(0)
Sign in
to like and join the discussion.
No comments yet. Be the first to comment.
Related publications
Preprint
2022
Author response for "Sodium‐glucose co‐transporter 2 inhibitors: An additional management option for patients with atrial fibrillation?"
Riccardo Proietti
,
Professor Gregory Lip
Article
2025
Sodium-Glucose Cotransporter-2 Inhibitors and Arrhythmias
Vikash Jaiswal
,
Song Peng Ang
,
Danisha Kumar
,
Novonil Deb
,
Akash Jaiswal
,
Amey Joshi
,
Yusra Nasir
,
Dhrubajyoti Bandyopadhyay
,
Erin D. Michos
,
Emelia Benjamin
,
Gregg C. Fonarow
Article
2023
Outcomes associated with sodium glucose co-transporter 2 inhibitors in anticoagulated atrial fibrillation patients
Ameenathul M. Fawzy
,
Arnaud Bisson
,
L Fauchier
,
Professor Gregory Lip
Letter
2024
Cardiovascular and Renal Benefit of Sodium-Glucose Cotransporter Type 2 Inhibitors in Patients With Type 2 Diabetes
Steven Ho Man Lam
,
Uazman Alam
,
Professor Gregory Lip
Article
2025
Sodium Glucose Cotransporter 2 Inhibitors Across the Spectrum of Cardiovascular Kidney Metabolic Syndrome
Kevin Bryan Lo
,
Karim Iskarous
,
Rajiv Sankaranarayanan
Discussion(0)
No comments yet. Be the first to comment.